Featured Research

from universities, journals, and other organizations

Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer

Date:
April 12, 2001
Source:
Rush Presbyterian St. Luke's Medical Center
Summary:
Breast cancer researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have begun testing a new therapy that targets the blood vessels that feed breast cancer tumors. This new antiangiogenic therapy, called rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) seeks to block cancer's ability to form new blood vessels that feed the tumor.

Breast cancer researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have begun testing a new therapy that targets the blood vessels that feed breast cancer tumors.

This new antiangiogenic therapy, called rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) seeks to block cancer's ability to form new blood vessels that feed the tumor.

Antiangiogenic therapy is a relatively new form of cancer treatment using drugs called angiogenesis inhibitors' that specifically halt new blood vessel growth and starve a tumor by cutting off its blood supply.

"If a tumor develops but has no blood supply, it will typically only grow to the size of a small pea," said principle investigator Dr. Melody Cobleigh, director of the Comprehensive Breast Center at Rush-Presbyterian-St. Luke's Medical Center in Chicago.

However, if the tumor is not detected and treated, eventually a few cancer cells gain the ability to produce proteins known as angiogenic growth factors. These 'growth factors' are released by the tumor into nearby tissues and they stimulate new blood vessels to sprout from existing healthy blood vessels, into the tumor. The tumor is then able to rapidly expand in size.

Patients enrolled in the trial at Rush will be randomly assigned to one of two treatment groups: one group will receive chemotherapy that is known to work against breast cancer. Another group will receive rhuMAb VEGF intravenously and chemotherapy.

RhuMAb VEGF was studied in women with breast cancer who had worsened on chemotherapy. Those early studies produced promising results. Researchers hope that by combining it with chemotherapy, they will get a better result than by using chemotherapy alone. The chemotherapy will attack the tumor while the rhuMAb VEGF will squeeze its blood supply.

Currently, approximately 20 anti-angiogenesis inhibitors are being tested in human cancer patients in clinical trials but there are no such drugs approved for clinical use by the Food and Drug Administration. Approximately 6,500 patients have taken one of these anti-angiogenic drugs to treat cancer.

Anti-angiogenesis inhibitors are also promising, according to the National Cancer Institute, because they are not as likely to cause bone marrow suppression, gastrointestinal symptoms, or hair loss -- symptoms characteristic of standard chemotherapy treatments. Additionally, these therapies target normal endothelial cells, which are genetically stable, so drug resistance may not develop. So far, resistance has not been a major problem in long-term animal studies or in preliminary clinical trials.

For more information about angiogenesis inhibitors, visit the National Cancer Insitutes' webpage at: http://cancertrials.nci.nih.gov/news/angio/fsangio.html

Rush-Presbyterian-St. Luke's Medical Center includes the 809-bed Presbyterian-St. Luke's Hospital; 154-bed Johnston R. Bowman Health Center for the Elderly; Rush University (Rush Medical College, College of Nursing, College of Health Sciences and Graduate College); and seven Rush Institutes providing diagnosis, treatment and research into leading health problems. The medical center is the tertiary hub of the Rush System for Health, a comprehensive healthcare system capable of serving about two million people through its outpatient facilities and five member hospitals.


Story Source:

The above story is based on materials provided by Rush Presbyterian St. Luke's Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush Presbyterian St. Luke's Medical Center. "Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer." ScienceDaily. ScienceDaily, 12 April 2001. <www.sciencedaily.com/releases/2001/04/010412081112.htm>.
Rush Presbyterian St. Luke's Medical Center. (2001, April 12). Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2001/04/010412081112.htm
Rush Presbyterian St. Luke's Medical Center. "Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2001/04/010412081112.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) — A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Raw: World's Oldest Man Lives in Japan

Raw: World's Oldest Man Lives in Japan

AP (Aug. 20, 2014) — A 111-year-old Japanese was certified as the world's oldest man by Guinness World Records on Wednesday. Sakari Momoi, a native of Fukushima in northern Japan, was given a certificate at a hospital in Tokyo. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Do More Wedding Guests Make A Happier Marriage?

Do More Wedding Guests Make A Happier Marriage?

Newsy (Aug. 20, 2014) — A new study found couples who had at least 150 guests at their weddings were more likely to report being happy in their marriages. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) — Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins